mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar | Nature Medicine
Should FDA Reconsider Allowing the Pooling of COVID-19 Vaccine Doses to Obtain Additional Doses? | Institute For Safe Medication Practices
SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people - ScienceDirect
I got AstraZeneca for my first dose. Which should I get for my second?' A COVID vaccination guide - Healthy Debate
Covid: Single jab recommended for 12 to 15-year-olds by UK's top doctors - BBC News
Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials | Infectious Diseases of Poverty | Full Text
Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study - The Lancet Regional Health – Americas
COVID-19 Vaccine Information | County of Fresno
COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons — United States, December 14, 2020−February 14, 2021 | MMWR
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine | NEJM
Comparison between one and two dose SARS-CoV-2 vaccine prioritization for a fixed number of vaccine doses | Journal of The Royal Society Interface
Hepatitis B Foundation: Hepatitis B Vaccine Schedules
Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Year
Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine | NEJM
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults | Nature
Covid-19 Vaccine Tracker: Latest Updates - The New York Times
Ibuprofen Dosing Table for Fever and Pain - HealthyChildren.org
Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study | The BMJ
Hepatitis B Foundation: Hepatitis B Vaccine Schedules
Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021 | MMWR
Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study | The BMJ
Who Didn't Get a Second Shingrix Shot? Implications for Multidose COVID-19 Vaccines | KFF
